» Articles » PMID: 36931289

Improving Health Outcomes of People with Diabetes: Target Setting for the WHO Global Diabetes Compact

Abstract

The Global Diabetes Compact is a WHO-driven initiative uniting stakeholders around goals of reducing diabetes risk and ensuring that people with diabetes have equitable access to comprehensive, affordable care and prevention. In this report we describe the development and scientific basis for key health metrics, coverage, and treatment targets accompanying the Compact. We considered metrics across four domains: factors at a structural, system, or policy level; processes of care; behaviours and biomarkers such as glycated haemoglobin (HbA); and health events and outcomes; and three risk tiers (diagnosed diabetes, high risk, or whole population), and reviewed and prioritised them according to their health importance, modifiability, data availability, and global inequality. We reviewed the global distribution of each metric to set targets for future attainment. This process led to five core national metrics and target levels for UN member states: (1) of all people with diabetes, at least 80% have been clinically diagnosed; and, for people with diagnosed diabetes, (2) 80% have HbA concentrations below 8·0% (63·9 mmol/mol); (3) 80% have blood pressure lower than 140/90 mm Hg; (4) at least 60% of people 40 years or older are receiving therapy with statins; and (5) each person with type 1 diabetes has continuous access to insulin, blood glucose meters, and test strips. We also propose several complementary metrics that currently have limited global coverage, but warrant scale-up in population-based surveillance systems. These include estimation of cause-specific mortality, and incidence of end-stage kidney disease, lower-extremity amputations, and incidence of diabetes. Primary prevention of diabetes and integrated care to prevent long-term complications remain important areas for the development of new metrics and targets. These metrics and targets are intended to drive multisectoral action applied to individuals, health systems, policies, and national health-care access to achieve the goals of the Global Diabetes Compact. Although ambitious, their achievement can result in broad health benefits for people with diabetes.

Citing Articles

Temporal Trends in the Burden of Diabetes and Its Risk Factors Across the Western Pacific Region Between 1990 and 2044: A Systematic Analysis of the Global Burden of Disease Study 2019.

Liu X, Wu B, Lai Y, Zhang X, Li H, Qu F Diabetes Metab Res Rev. 2025; 41(2):e70036.

PMID: 39983069 PMC: 11845174. DOI: 10.1002/dmrr.70036.


Investigating the role of gut microbiota in diabetic nephropathy through plasma proteome mediated analysis.

Fu S, Li F, Yu J, Ma S, Zhang L, Cheng Y Sci Rep. 2025; 15(1):5457.

PMID: 39953202 PMC: 11828962. DOI: 10.1038/s41598-025-90306-7.


Multiple long-term conditions as the next transition in the global diabetes epidemic.

Gregg E, Holman N, Sophiea M, Misra S, Pearson-Stuttard J, Valabhji J Commun Med (Lond). 2025; 5(1):42.

PMID: 39953177 PMC: 11828996. DOI: 10.1038/s43856-025-00742-9.


Mind the gap in kidney care: translating what we know into what we do.

Luyckx V, Tuttle K, Abdellatif D, Correa-Rotter R, Fung W, Haris A Kidney Res Clin Pract. 2025; 44(1):6-19.

PMID: 39815796 PMC: 11838860. DOI: 10.23876/j.krcp.24.100.


Latent class analysis of the capacity of countries to manage diabetes and its relationship with diabetes-related deaths and healthcare costs.

Akyirem S, Ekpor E, Kwanin C BMC Health Serv Res. 2025; 25(1):83.

PMID: 39815276 PMC: 11734536. DOI: 10.1186/s12913-024-12052-2.


References
1.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

2.
Haw J, Galaviz K, Straus A, Kowalski A, Magee M, Weber M . Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2017; 177(12):1808-1817. PMC: 5820728. DOI: 10.1001/jamainternmed.2017.6040. View

3.
. Health systems, patients factors, and quality of care for diabetes: a synthesis of findings from the TRIAD study. Diabetes Care. 2010; 33(4):940-7. PMC: 2845056. DOI: 10.2337/dc09-1802. View

4.
Zhou X, Siegel K, Ng B, Jawanda S, Proia K, Zhang X . Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care. 2021; 43(7):1593-1616. DOI: 10.2337/dci20-0018. View

5.
Karpati T, Cohen-Stavi C, Leibowitz M, Hoshen M, Feldman B, Balicer R . Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel. Popul Health Metr. 2014; 12(1):32. PMC: 4233034. DOI: 10.1186/s12963-014-0032-y. View